List of Excipients in Branded Drug PROCARDIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	PROCARDIA	nifedipine	0069-2600	FD&C YELLOW NO. 6
Pfizer Laboratories Div Pfizer Inc	PROCARDIA	nifedipine	0069-2600	FERRIC OXIDE RED
Pfizer Laboratories Div Pfizer Inc	PROCARDIA	nifedipine	0069-2600	GLYCERIN
Pfizer Laboratories Div Pfizer Inc	PROCARDIA	nifedipine	0069-2600	PEPPERMINT OIL
Pfizer Laboratories Div Pfizer Inc	PROCARDIA	nifedipine	0069-2600	POLYETHYLENE GLYCOL
Pfizer Laboratories Div Pfizer Inc	PROCARDIA	nifedipine	0069-2600	SACCHARIN SODIUM
Pfizer Laboratories Div Pfizer Inc	PROCARDIA	nifedipine	0069-2600	WATER

Procardia Excipient Strategy and Commercial Opportunities for Nifedipine Formulations

Last updated: August 27, 2026

Procardia is Pfizer’s brand for nifedipine, a dihydropyridine calcium-channel blocker. Its commercial value is concentrated in two formulation platforms: immediate-release nifedipine capsules and Procardia XL extended-release osmotic tablets. The active pharmaceutical ingredient is long off-patent, so current opportunities depend on formulation performance, bioequivalence, manufacturing reliability, excipient differentiation, and regulatory execution rather than compound exclusivity.

What formulations does Procardia use?

Procardia has used two technically distinct delivery systems.

Product	Active ingredient	Dosage form	Release profile	Primary excipient strategy
Procardia	Nifedipine	Soft gelatin capsule	Immediate release	Liquid-filled capsule with solvent and plasticizer system
Procardia XL	Nifedipine	Extended-release tablet	Once-daily controlled release	Osmotic delivery platform with hydrophilic polymers, osmogen, coating and precision orifice

The immediate-release capsule is designed to dissolve and release nifedipine rapidly. Procardia XL uses a controlled-release tablet that delivers nifedipine over an extended period. The Procardia XL tablet shell may be visible in feces after the drug has been released, according to the prescribing information.[1]

Nifedipine has low aqueous solubility, making solvent selection, wetting, particle size and dissolution control central to product performance. The immediate-release softgel and the extended-release osmotic tablet solve this problem through different excipient architectures.

What excipients are used in Procardia and Procardia XL?

Procardia immediate-release capsule excipients

The Procardia capsule uses a soft gelatin system. Listed inactive ingredients include gelatin, glycerin and polyethylene glycol 400, together with colorants and other capsule components identified in the product labeling.[1,2]

The commercial purpose of these excipients is functional:

• Gelatin forms the elastic capsule shell.
• Glycerin acts as a plasticizer.
• Polyethylene glycol 400 functions as a liquid vehicle and solvent.
• Colorants support product identification and strength differentiation.
• The liquid fill supports rapid dispersion after shell rupture.

This platform creates a relatively simple generic pathway compared with Procardia XL. The main development risks are fill uniformity, capsule-shell compatibility, nifedipine precipitation after dilution, photostability, content uniformity and dissolution.

Procardia XL excipients

Procardia XL labeling identifies a controlled-release system containing nifedipine with hydrophilic polymer, osmotic, lubricant and coating components. The listed inactive ingredients include hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyethylene oxide, sodium chloride, magnesium stearate, polyethylene glycol, titanium dioxide and red ferric oxide.[1,2]

Their formulation roles are different:

Excipient class	Representative Procardia XL component	Technical function
Swellable or gel-forming polymer	Hydroxypropyl methylcellulose	Controls hydration and matrix or membrane behavior
High-viscosity osmotic polymer	Polyethylene oxide	Supports controlled drug-layer expansion and delivery
Osmogen	Sodium chloride	Generates osmotic pressure
Binder or processing polymer	Hydroxypropyl cellulose	Supports granulation and tablet integrity
Lubricant	Magnesium stearate	Reduces punch and die friction
Coating materials	Hypromellose, polyethylene glycol, titanium dioxide, iron oxide	Provides film protection, appearance and processing performance

The precise release mechanism depends on the product design and manufacturing process. For generic development, excipient identity alone is insufficient. Polymer grade, molecular-weight distribution, substitution pattern, particle size, moisture, compression force, coating weight and delivery-orifice dimensions can materially affect release.

What excipient strategy is required for a Procardia XL generic?

A Procardia XL generic needs a controlled-release strategy that reproduces the reference product’s in vitro and in vivo behavior. The highest-value excipient decisions are the following.

Polymer grade selection

Polyethylene oxide and hypromellose are not interchangeable commodities. Viscosity grade, molecular weight and hydration rate can change the release curve. Two products with the same nominal polymer concentration may have different early release, terminal release and variability.

A generic manufacturer should qualify multiple grades of each critical polymer and establish a design space linking:

• Polymer molecular weight and viscosity
• Polymer-to-drug ratio
• Sodium chloride concentration
• Tablet hardness
• Coating weight gain
• Orifice dimensions
• Dissolution behavior under pH and agitation changes

Osmotic balance

Sodium chloride or another osmogen controls water influx and internal osmotic pressure. Excessive osmogen loading can accelerate release or increase variability. Insufficient osmogen loading can produce incomplete delivery or an overly slow profile.

The product must also be assessed under alcohol exposure. Modified-release oral products can present dose-dumping risks if alcohol alters polymer hydration, membrane permeability or tablet integrity. Alcohol robustness is a commercial and regulatory screening requirement even where it is not the primary differentiator.

Lubrication control

Magnesium stearate is necessary for manufacturability but can reduce wettability when overused or excessively blended. Longer lubrication times may affect granule surfaces and slow hydration. This is a common source of scale-up variability in hydrophilic controlled-release products.

Coating and delivery-orifice control

The coating must protect the tablet, provide consistent surface properties and support the intended release mechanism. Coating weight, film uniformity and curing conditions can influence water permeability.

If the system uses a precision delivery opening, the orifice process becomes a critical quality attribute. Laser drilling, mechanical drilling or alternative manufacturing methods can create different defect profiles and require separate validation.

What formulation patents protect Procardia XL?

The nifedipine molecule and the original immediate-release product are long off-patent. Historical protection for controlled-release nifedipine focused on delivery systems, osmotic technology, polymer architecture and manufacturing methods rather than new chemical matter.

The practical patent position is:

Patent category	Current commercial relevance
Nifedipine compound patents	Expired
Immediate-release capsule technology	Expired or commercially weak
Historical osmotic delivery patents	Generally expired for the original Procardia XL platform
New generic formulation patents	Potentially available for differentiated delivery, manufacturing or stability improvements
Method-of-use patents	Limited value where approved hypertension and angina uses are longstanding
Excipient composition patents	Possible for new polymers, coatings, solubilizers or delivery systems

The FDA Orange Book is the controlling source for current listed patents and regulatory exclusivities.[3] A company assessing launch risk should review current listings for Procardia and Procardia XL, including patent-use codes, delisting activity and any litigation certifications. Historical Procardia XL patents do not create a continuing compound-level barrier.

When does Procardia lose exclusivity?

Procardia lost meaningful market exclusivity decades ago. Nifedipine is a small molecule, so biosimilar exclusivity does not apply. The relevant competitive pathway is an abbreviated new drug application, or ANDA, for generic nifedipine capsules or extended-release tablets.

Exclusivity category	Procardia status
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current commercial significance
Orphan-drug exclusivity	Not applicable to the core product
Reference-product exclusivity	Expired
Patent protection on nifedipine	Expired
Biosimilar exclusivity	Not applicable
Current commercial barrier	Formulation, bioequivalence and manufacturing execution

Generic applicants still face product-specific regulatory requirements. For immediate-release capsules, applicants generally need to demonstrate pharmaceutical equivalence and bioequivalence. For extended-release products, dissolution profile matching, pharmacokinetic studies and manufacturing controls are more demanding.

What is the Orange Book status of Procardia?

Procardia and Procardia XL are FDA-approved prescription products with historical Orange Book listings. The Orange Book identifies reference-listed drugs, dosage forms, strengths, approved applicants and any current patent or exclusivity information.[3]

For commercial diligence, the key distinction is between:

1. A historical patent associated with the branded product.
2. A currently listed, unexpired patent that can support a Paragraph IV dispute.
3. A formulation or method patent owned by a third party that is not listed for the reference product.
4. A patent covering a new generic or reformulated product.

A current ANDA applicant should not assume that the absence of a meaningful compound patent eliminates all launch risk. Extended-release nifedipine remains vulnerable to formulation-related deficiencies, failed bioequivalence, dissolution mismatch, manufacturing observations and postapproval product-quality problems.

Which companies are challenging Procardia?

Generic nifedipine products are widely marketed by multiple manufacturers. Competition includes products equivalent to immediate-release nifedipine capsules and several extended-release nifedipine tablet platforms. The branded Procardia franchise does not have the concentrated competitive structure associated with a still-patented specialty product.

The key competitors are generic manufacturers with capabilities in:

• Softgel manufacturing
• Hydrophilic matrix tablets
• Osmotic controlled-release systems
• High-volume cardiovascular products
• ANDA portfolio management
• Multi-source contracting and pharmacy distribution

The most relevant competitive question is not which company first challenged Procardia. It is which manufacturer can maintain a low-cost, reliable product while meeting extended-release dissolution specifications across commercial scale.

What patent litigation and Paragraph IV risks affect Procardia?

The original Procardia franchise does not present the patent litigation profile of a recently approved drug. A Paragraph IV challenge would be relevant only if a current unexpired Orange Book patent were listed or if a separate patent dispute arose around a new formulation.

Potential litigation triggers include:

• A newly listed controlled-release formulation patent
• A patent covering a specific osmotic architecture
• A manufacturing patent involving polymer processing or laser drilling
• A patent covering a reformulated nifedipine product
• A regulatory dispute over whether a generic product is therapeutically equivalent

For the established products, the primary risk is regulatory rather than patent-based. Generic launch timing is more likely to be determined by ANDA review, complete response letters, inspection outcomes and manufacturing readiness than by an injunction over the original nifedipine molecule.

What commercial opportunities exist in Procardia excipients?

Low-cost generic supply

The largest opportunity is supplying high-volume excipients used in generic nifedipine products. Critical materials include:

• Pharmaceutical-grade polyethylene oxide
• Hypromellose with controlled viscosity
• Hydroxypropyl cellulose
• Sodium chloride meeting tight particle and impurity specifications
• Softgel-grade gelatin
• Glycerin
• Polyethylene glycol 400
• Film-coating polymers and pigments

Supply continuity has commercial value because controlled-release products can require extensive revalidation after changes to polymer grade or supplier.

Excipient substitution and dual sourcing

A supplier that qualifies equivalent polymer grades, low-moisture materials or improved lot-to-lot consistency can support generic manufacturers seeking second sources. The strongest opportunity is not simply a lower unit price. It is a documented equivalence package covering viscosity, hydration, dissolution impact, elemental impurities, microbial quality and stability.

New oral delivery systems

Companies can pursue 505(b)(2) or reformulation strategies involving:

• Smaller once-daily tablets
• Improved light protection
• Lower pill burden through combination products
• Sprinkle or liquid formulations
• Alternative softgel fills
• Improved dose flexibility
• Modified-release systems with lower variability
• Alcohol-resistant release profiles

Each option needs a clear clinical or adherence benefit. An excipient change alone rarely creates durable commercial value unless it improves pharmacokinetics, stability, tolerability, manufacturability or patient use.

Animal-health and international markets

Nifedipine has potential applications in markets where cardiovascular products are supplied through national tenders or private-label channels. Excipient suppliers can target regional manufacturers with local regulatory support, alternative gelatin sourcing, non-animal materials and packaging adapted to hot or humid climates.

Geographic opportunities are strongest where generic cardiovascular medicines have high volume and the regulatory burden for a differentiated product is manageable. U.S. entry remains attractive but requires higher development discipline for extended-release equivalence.

How strong is the Procardia patent estate?

The patent estate is weak as a barrier to generic entry because the compound, original dosage forms and historical controlled-release platform are mature technologies. Its residual value is primarily defensive and procedural.

Estate component	Strength against generic entry
Nifedipine composition of matter	None
Immediate-release capsule formulation	Low
Original osmotic controlled-release platform	Low
New manufacturing process patents	Potentially moderate
New excipient combinations	Potentially moderate if non-obvious and performance-linked
New clinical indication patents	Limited for established uses
Trade secrets and process know-how	Potentially meaningful at manufacturing scale

Trade secrets may have greater practical value than expired patents. These include polymer preconditioning, granulation endpoint control, coating parameters, laser-drilling settings and dissolution-release correlations.

How does Procardia compare with competing nifedipine products?

Attribute	Procardia capsule	Procardia XL	Generic nifedipine ER
Release	Immediate	Extended, once daily	Extended, platform-dependent
Formulation complexity	Moderate	High	Moderate to high
Main excipient risk	Liquid fill and shell compatibility	Polymer, osmotic and coating control	Equivalence to reference product
Patent barrier	None of practical significance	Historical patents largely expired	Product-specific patents may apply to new designs
Biosimilar risk	Not applicable	Not applicable	Not applicable
Commercial opportunity	Low-cost capsule supply	Higher-value controlled-release development	Broad generic volume and private-label supply

What generic launch scenarios exist for Procardia?

The most likely launch scenarios are:

1. Continued multi-source generic supply of immediate-release nifedipine capsules.
2. Expansion of generic extended-release tablets using hydrophilic or osmotic technologies.
3. Private-label and regional supply agreements.
4. Reformulated products targeting adherence, tablet size or stability.
5. Excipient-led differentiation supported by improved manufacturing consistency rather than new clinical claims.

A new entrant should expect price competition in immediate-release capsules. Extended-release products offer greater technical differentiation but require more extensive development, scale-up and regulatory control.

Key Takeaways

• Procardia is nifedipine; its compound patent and original exclusivity have expired.
• Procardia uses an immediate-release softgel platform, while Procardia XL uses an extended-release osmotic tablet.
• The most important excipients are polyethylene glycol 400, glycerin and gelatin in the capsule, and polyethylene oxide, hypromellose, sodium chloride, hydroxypropyl cellulose and coating materials in the XL tablet.
• Generic opportunity is strongest in controlled-release manufacturing, polymer supply, dual sourcing and differentiated oral delivery.
• The current risk profile is regulatory and technical, not based on an active compound patent.
• Nifedipine has no biosimilar pathway because it is a small molecule.
• Orange Book review remains necessary for any specific current ANDA or Paragraph IV strategy.
• Manufacturing know-how may provide more durable value than the historical Procardia patent estate.

FAQs

Can a generic manufacturer change the excipients in Procardia XL?

Yes. An ANDA applicant may use different excipients if the product meets applicable pharmaceutical equivalence, bioequivalence, quality and performance requirements. For extended-release nifedipine, excipient changes must not materially alter release or pharmacokinetics.

Which excipient is most important in nifedipine extended-release tablets?

Polyethylene oxide or another rate-controlling polymer is typically central to the release mechanism. Its grade, molecular weight, hydration behavior and concentration can materially affect dissolution.

Is nifedipine an FDA-designated biosimilar product?

No. Nifedipine is a chemically synthesized small molecule regulated through the generic-drug pathway, principally under an ANDA rather than a biosimilar application.

Can an excipient supplier patent a new Procardia formulation?

Potentially. A supplier or drug manufacturer may obtain patents on a novel excipient combination, delivery system, manufacturing process or stability improvement if the invention satisfies patentability requirements and produces a credible technical benefit.

Does Procardia XL still have a strong commercial brand premium?

The commercial premium is limited by broad generic availability. Value remains in physician recognition, distribution, contract supply and differentiated reformulations, but the original brand has little protection from generic substitution.

References

1. Pfizer Laboratories. (2022). Procardia and Procardia XL prescribing information. U.S. Food and Drug Administration.

2. National Library of Medicine. (n.d.). DailyMed: Procardia and Procardia XL product labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2019). Guidance for industry: Size, shape, and other physical attributes of generic tablets and capsules. Center for Drug Evaluation and Research.

5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.